Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Lenalidomide
Related studies linked through entity extraction aliases.
Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide
- Status
- TERMINATED
- Phase
- PHASE1
Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia
- Status
- TERMINATED
- Phase
- PHASE2
Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Lenalidomide as Consolidation and Maintenance in Adults >/= 60 Years of Age With AML Following Standard Induction
- Status
- COMPLETED
- Phase
- PHASE1
Maintenance Lenalidomide in Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE3
Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy
- Status
- COMPLETED
- Phase
- PHASE3
Lenalidomide in Relapsed or Refractory Primary-cutaneous Large B-cell Lymphoma Leg-type : Multicentre Prospective Phase II Single Arm Trial of the French Study Group of Cutaneous Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL)
- Status
- COMPLETED
- Phase
- PHASE2
Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
- Status
- COMPLETED
- Phase
- PHASE2
Lenalidomide as Second-line Treatment for Advanced Hepatocellular Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- EARLY_PHASE1
Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Lenalidomide and Low Dose Dexamethasone Versus Bortezomib, Lenalidomide and Low Dose Dexamethasone for Induction, in Patients With Previously Untreated Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE3